Processa Pharmaceuticals (PCSA) has provided an update.
Processa Pharmaceuticals, Inc. has appointed seasoned industry expert Russell Skibsted as their new Chief Financial Officer, effective July 16, 2024. Skibsted, with almost three decades of experience in the pharmaceutical sector, is set to receive a $400,000 salary with potential bonuses and 28,000 restricted stock units, subject to the achievement of specified goals. His extensive background includes roles at Alimera Sciences and Rockwell Medical, among others. This strategic move follows the amicable resignation of the former CFO, James Stanker, who will assist part-time during the transition.
See more insights into PCSA stock on TipRanks’ Stock Analysis page.
